Robocath Completes First-in-Human Enrollment for Next-Generation Robotic PCI System in France

Robocath has closed enrollment in its first-in-human clinical study for a next-generation robotic-assisted percutaneous coronary intervention platform, a milestone that moves the device closer to the regulatory submissions required for broader clinical deployment in interventional cardiology.

The study, conducted at a site in France, evaluated safety and feasibility across complex cardiac cases — the patient population that most directly tests the mechanical reliability and procedural consistency of robotic catheter systems. Enrollment completion marks the transition from active recruitment to data collection and analysis, the phase that will underpin any future conformity assessment or CE marking pathway under the EU Medical Device Regulation.

For quality and regulatory leads tracking robotic-assisted intervention, the study design's focus on complex cases is operationally significant. Feasibility data drawn from high-acuity procedures carries more weight in benefit-risk assessments than data from straightforward anatomy, and regulators reviewing technical documentation under MDR 2017/745 will scrutinize that case mix when evaluating clinical evidence sufficiency.

Robocath has not disclosed the study's sample size, primary endpoints, or anticipated data readout timeline, limiting external assessment of the evidence package at this stage. The absence of those details means device manufacturers, hospital procurement leads, and regulatory affairs teams monitoring the robotic PCI space will need to await a formal clinical data release before drawing conclusions about the platform's performance profile.

The completion of enrollment positions Robocath to move toward a clinical data package that will define the regulatory and commercial trajectory of the platform across European and potentially broader markets.

Source: Media4Growth via Indian Pharma Post, 10 May 2026.